ConforMIS Inc (NASDAQ:CFMS) Major Shareholder Sells $1,052,934.61 in Stock
ConforMIS Inc (NASDAQ:CFMS) major shareholder Archon Capital Management Llc sold 279,293 shares of the firm’s stock in a transaction dated Tuesday, July 9th. The stock was sold at an average price of $3.77, for a total value of $1,052,934.61. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
Archon Capital Management Llc also recently made the following trade(s):
- On Thursday, July 11th, Archon Capital Management Llc sold 151,022 shares of ConforMIS stock. The stock was sold at an average price of $3.76, for a total value of $567,842.72.
NASDAQ:CFMS opened at $3.67 on Friday. The company has a debt-to-equity ratio of 0.64, a current ratio of 3.00 and a quick ratio of 2.33. ConforMIS Inc has a 12-month low of $0.36 and a 12-month high of $4.83. The stock’s 50-day simple moving average is $4.00. The stock has a market capitalization of $253.13 million, a PE ratio of -4.96 and a beta of 2.30.
Several research firms have recently commented on CFMS. Oppenheimer decreased their price objective on Littelfuse from $215.00 to $210.00 and set an “outperform” rating on the stock in a research note on Thursday, May 2nd. Zacks Investment Research upgraded HB Fuller from a “sell” rating to a “hold” rating in a research report on Wednesday, July 3rd. BTIG Research increased their target price on Yum! Brands to $114.00 and gave the stock a “buy” rating in a research report on Thursday, May 2nd. ValuEngine upgraded Vistra Energy from a “hold” rating to a “buy” rating in a research report on Wednesday, July 3rd. Finally, BidaskClub cut Xperi from a “sell” rating to a “strong sell” rating in a research report on Wednesday, June 19th. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $3.40.
Several large investors have recently added to or reduced their stakes in the stock. Spark Investment Management LLC grew its position in shares of ConforMIS by 172.2% during the first quarter. Spark Investment Management LLC now owns 500,000 shares of the medical instruments supplier’s stock worth $1,440,000 after purchasing an additional 316,300 shares in the last quarter. Altrinsic Global Advisors LLC grew its holdings in ConforMIS by 11.7% during the 1st quarter. Altrinsic Global Advisors LLC now owns 478,942 shares of the medical instruments supplier’s stock valued at $1,379,000 after buying an additional 50,000 shares in the last quarter. Tibra Equities Europe Ltd purchased a new position in ConforMIS during the 1st quarter valued at approximately $381,000. Acadian Asset Management LLC grew its holdings in ConforMIS by 26.0% during the 4th quarter. Acadian Asset Management LLC now owns 127,166 shares of the medical instruments supplier’s stock valued at $45,000 after buying an additional 26,202 shares in the last quarter. Finally, Creative Planning grew its holdings in ConforMIS by 133.8% during the 1st quarter. Creative Planning now owns 116,922 shares of the medical instruments supplier’s stock valued at $337,000 after buying an additional 66,922 shares in the last quarter. Hedge funds and other institutional investors own 34.11% of the company’s stock.
ConforMIS Company Profile
Conformis, Inc, a medical technology company, develops, manufactures, and sells joint replacement implants. The company offers customized knee replacement products, including iTotal CR, a cruciate-retaining product; iTotal PS, a posterior cruciate ligament substituting product; iDuo, a customized bicompartmental knee replacement system; and iUni, a customized unicompartmental knee replacement product to treat the medial or lateral compartment of the knee.
Recommended Story: What does a bar chart display?
Receive News & Ratings for ConforMIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConforMIS and related companies with MarketBeat.com's FREE daily email newsletter.